MA44763A - Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang - Google Patents

Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang

Info

Publication number
MA44763A
MA44763A MA044763A MA44763A MA44763A MA 44763 A MA44763 A MA 44763A MA 044763 A MA044763 A MA 044763A MA 44763 A MA44763 A MA 44763A MA 44763 A MA44763 A MA 44763A
Authority
MA
Morocco
Prior art keywords
antigen
antibodies
intended
pharmaceutical compositions
dendritic cell
Prior art date
Application number
MA044763A
Other languages
English (en)
French (fr)
Inventor
David Dai
Mark R H Krebs
David Martin
Dania Rabah
Shantanu Sule
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA44763A publication Critical patent/MA44763A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA044763A 2016-04-28 2017-04-27 Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang MA44763A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28

Publications (1)

Publication Number Publication Date
MA44763A true MA44763A (fr) 2019-03-06

Family

ID=58672794

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044763A MA44763A (fr) 2016-04-28 2017-04-27 Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang

Country Status (14)

Country Link
US (2) US20190284281A1 (enExample)
EP (1) EP3448425A1 (enExample)
JP (4) JP7045327B2 (enExample)
KR (5) KR20220028150A (enExample)
CN (2) CN109475623B (enExample)
AU (2) AU2017258191B2 (enExample)
CA (1) CA3022116A1 (enExample)
CO (1) CO2018012506A2 (enExample)
EA (1) EA201892443A1 (enExample)
IL (2) IL262514B2 (enExample)
MA (1) MA44763A (enExample)
MX (3) MX2018012945A (enExample)
PH (1) PH12018502278A1 (enExample)
WO (1) WO2017189827A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49962A (fr) * 2017-08-22 2020-07-01 Biogen Ma Inc Procédés de purification d'anticorps présentant des agrégats réduits à poids moléculaire élevé
ES3014697T3 (en) 2018-07-19 2025-04-24 Ichnos Sciences S A Liquid antibody formulation
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
CN116963716A (zh) * 2020-12-03 2023-10-27 渤健马萨诸塞州股份有限公司 治疗皮肤型红斑狼疮和系统性红斑狼疮的方法
KR20230022786A (ko) 2021-08-09 2023-02-16 주식회사 인벤테라제약 생체 내 주입 후 대식세포에 의해 탐식 및/또는 대사분해되지 않은 상태로 신장을 통해 소변으로 배출되는 나노 구조물
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥（蘇州）有限公司 抗ｂｄｃａ２抗體及其用途
WO2024140838A1 (zh) * 2022-12-28 2024-07-04 映恩生物制药（苏州）有限公司 抗bdca2抗体-药物偶联物及其用途
IL327431A (en) * 2023-09-28 2026-05-01 Nanjing Leads Biolabs Co Ltd BDCA2 monoclonal antibody, fusion protein consisting of the same antibody and TACI and method and use thereof
WO2026008012A1 (zh) * 2024-07-04 2026-01-08 杭州博之锐生物制药有限公司 抗bdca2抗体及其用途
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
BR122020023058B1 (pt) 2012-12-10 2023-12-05 Biogen Ma Inc Ácido nucleico isolado ou ácidos nucleicos

Also Published As

Publication number Publication date
IL262514A (en) 2018-12-31
MX2025000037A (es) 2025-02-10
IL262514B2 (en) 2025-12-01
JP2019520316A (ja) 2019-07-18
BR112018072125A2 (pt) 2019-03-19
KR102366547B1 (ko) 2022-02-23
CN109475623B (zh) 2023-05-26
IL262514B1 (en) 2025-08-01
MX2018012945A (es) 2019-03-06
JP7045327B2 (ja) 2022-03-31
KR20240159012A (ko) 2024-11-05
AU2017258191A1 (en) 2018-11-15
CN109475623A (zh) 2019-03-15
IL321561A (en) 2025-08-01
CN116850282A (zh) 2023-10-10
NZ787392A (en) 2025-08-29
JP2024038308A (ja) 2024-03-19
MX2023008075A (es) 2023-07-18
AU2017258191B2 (en) 2024-06-13
EP3448425A1 (en) 2019-03-06
KR20240033168A (ko) 2024-03-12
NZ747504A (en) 2025-08-29
CO2018012506A2 (es) 2018-12-14
AU2024203240A1 (en) 2024-06-13
PH12018502278A1 (en) 2019-09-09
JP2022084782A (ja) 2022-06-07
US20190284281A1 (en) 2019-09-19
KR20190002563A (ko) 2019-01-08
CA3022116A1 (en) 2017-11-02
EA201892443A1 (ru) 2019-04-30
WO2017189827A1 (en) 2017-11-02
KR20250088784A (ko) 2025-06-17
KR20220028150A (ko) 2022-03-08
JP2026094462A (ja) 2026-06-09
US20250289895A1 (en) 2025-09-18

Similar Documents

Publication Publication Date Title
EP3840730A4 (en) COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND METHOD OF USE AND MANUFACTURING THEREOF
EP3630145A4 (en) PHARMACEUTICAL COMPOSITIONS OF CANNABIDIOL AND BETA-CARYOPHYLLENE AND METHOD FOR USING THEM
EP3716945A4 (en) LIQUID DOSAGE FORMS, METHOD OF MANUFACTURING AND USE
IL321561A (en) Pharmaceutical formulations and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
EP3528823A4 (en) DETERMINIST LATERAL SHIFTING IN THE PRODUCTION OF CELLS AND COMPOSITIONS FOR THERAPEUTIC USE
MA51796A (fr) Procédés et compositions pour l'administration de protéines thérapeutiques
EP3731868A4 (en) ANTI-TIGIT ANTIBODIES AND USE OF THEM AS THERAPEUTICS AND DIAGNOSTICS
EP3645742A4 (en) Anti-ror1 antibodies and methods of making and using thereof
MA45280A (fr) Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
EP3897564A4 (en) TISSUE FILLERS OF SILK HYALURONIC ACID AND METHODS OF MANUFACTURE AND USE THEREOF
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
EP3400013A4 (en) CADHERIN-17 SPECIFIC ANTIBODIES AND CYTOTOXIC CELL TREATMENT CELLS
EP2874642A4 (en) Anti-inflammatory proteins and peptides, and methods for their preparation and use
EP3626239A4 (en) USING AN EZH2 INHIBITOR IN COMBINATION WITH A BTK INHIBITOR TO MANUFACTURE A MEDICINAL PRODUCT FOR TUMOR TREATMENT
EP3380525A4 (en) PHARMACEUTICAL FORMULATIONS AND METHOD FOR USE THEREOF
EP3699192A4 (en) ANTI-CD3 ANTIBODIES AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT WITH IT
MA55090A (fr) Anticorps capable de se lier à la calréticuline mutante tronquée, et médicament de diagnostic, prophylactique ou thérapeutique pour néoplasmes myéloprolifératifs
EP3672587A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
EP4079761A4 (en) Anti-cea antibody-exatecan analog conjugate and pharmaceutical use thereof
MA41326A (fr) Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
MA55033A (fr) Formulation d'anticorps thérapeutique
EP3418305A4 (en) METHOD OF EXPRESSING AND PREPARING BIVALENT BISPEICIFIC ANTIBODY HYBRID PROTEIN
EP3523333A4 (en) ANTI-CEACAM6 ANTIBODIES AND METHOD FOR USE
MA53333A (fr) Formulations pharmaceutiques d'anticorps masqués
EP3664797A4 (en) NR4A1 LIGANDS, PHARMACEUTICAL COMPOSITIONS, AND RELATED METHODS OF USE